Cardiovascular drugs are instrumental in the comprehensive management of various heart and vascular conditions. These pharmaceutical interventions are formulated to intricately modulate the cardiovascular system, addressing issues like blood pressure regulation, cholesterol reduction, and the treatment of diverse cardiovascular disorders. Among the array of cardiovascular drugs, calcium channel blockers stand out, effectively relaxing blood vessels and reducing the heart's workload. Another essential class is diuretics, which assist in flushing excess salt and water from the body, ultimately lowering blood pressure. Vasodilators, designed to widen blood vessels, are also crucial components in the pharmacological approach to cardiovascular health. The dynamic field of cardiovascular medicine continually explores innovative drug therapies to enhance patient outcomes, emphasizing the importance of tailored treatment plans and close monitoring by healthcare professionals. Patients receiving cardiovascular drugs should actively engage in their prescribed regimen, prioritize regular medical evaluations, and adopt lifestyle modifications to optimize overall cardiovascular well-being.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation